Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: Immunohistochemical analysis of endometrial samples

International Journal of Gynecological Cancer

Volumn 22, Issue 7, 2012, Pages 1264-1272

  Robbe, Elisabeth J M ^a   Van Kuijk, Sander M J ^b,c   De Boed, Ella M ^d   Smits, Luc J M ^b   Van Der Wurff, Anneke A M ^d   Kruitwagen, Roy F P M ^c   Pijnenborg, Johanna M A ^d  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d CPRLab   (Netherlands)

Author keywords

Atypical endometrial hyperplasia; Coexistent carcinoma; Endometrial carcinoma; Immunohistochemistry; Prediction; PTEN

Indexed keywords

BETA CATENIN; CD44V ANTIGEN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; TENASCIN; UVOMORULIN; TUMOR MARKER;

ADULT; AGED; BODY MASS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; ADENOCARCINOMA; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; MULTIPLE CANCER; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84873246247     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31826302a3     Document Type: Conference Paper

References (57)

1. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32:569-577.
2. Widra EA, Dunton CJ, McHugh M, et al. Endometrial hyperplasia and the risk of carcinoma. Int J Gynecol Cancer. 1995;5:233-235.
3. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer. 1982;49:2547-2559.
4. Lacey JVJ, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63:39-44.
5. Allison KH, Tenpenny E, Reed SD, et al. Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. Appl Immunohistochem Mol Morphol. 2008;16:329-343.
6. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985;56:403-412.
7. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv. 2004;59: 368-378.
8. Marsden DE, Hacker NF. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol. 2001;15: 393-405.
9. Clark TJ, Voit D, Gupta JK, et al. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002;288: 1610-1621.
10. Garuti G, Mirra M, Luerti M. Hysteroscopic view in atypical endometrial hyperplasias: a correlation with pathologic findings on hysterectomy specimens. J Minim Invasive Gynecol. 2006;13:325-330.
11. Dunton CJ, Baak JP, Palazzo JP, et al. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol. 1996;174:1518-1521.
12. Ørbo A, Nilsen MN, Arnes MS, et al. Loss of expression of MLH1,MSH2,MSH6, andPTENrelated to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol. 2003;22:141-148.
13. Garcia FA, Davis JR, Alberts DS, et al. A karyometric approach to the characterization of atypical endometrial hyperplasia with and without co-occurring adenocarcinoma. Anal Quant Cytol Histol. 2003;25:339-346.
14. Ørbo A, Kaino T, Arnes M, et al. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. Gynecol Oncol. 2004;95:82-88.
15. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor0020lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58:3254-3258.
16. Esteller M, Garcia A, Martinez-Palones JM, et al. Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart. Lab Invest. 1997;76: 109-116.
17. Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol. 1999;155:1767-1772.
18. Ashihara K. Mutation of A-catenin gene in endometrial cancer but not in associated hyperplasia. Med Electron Microsc. 2002;35:9-15.
19. ctn) expression in endometrial cancer and endometrial hyperplasia. J Pathol. 2003;199: 471-478.
20. Scholten AN, Aliredjo R, Creutzberg CL, et al. Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer. 2006;16:1379-1385.
21. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol. 1998;29:1035-1038.
22. Risberg B, Karlsson K, Abeler V, et al. Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications. Int J Gynecol Pathol. 2002;21: 155-160.
23. Afify AM, Craig S, Paulino AF, et al. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol. 2005;9:312-318.
24. Fujita N, Yaegashi N, Ide Y, et al. Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res. 1994;54: 3922-3928.
25. Hoshimoto K, Yamauchi N, Takazawa Y, et al. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker. Pathol Res Pract. 2003;199:71-77.
26. Saegusa M, Hashimura M, Okayasu I. CD44 expression in normal, hyperplastic, and malignant endometrium. J Pathol. 1998;184:297-306.
27. Erkanli S, Kayaselcuk F, Kuscu E, et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer. 2006;16:1412-1418.
28. Ai Z, Yin L, Zhou X, et al. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer. 2006;107:746-756.
29. Kapucuoglu N, Aktepe F, Kaya H, et al. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract. 2007; 203:153-162.
30. Bozdogan O, Atasoy P, Erekul S, et al. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol. 2002;21: 375-382.
31. Cao QJ, Einstein MH, Anderson PS, et al. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol. 2002;21:147-154.
32. Nasir A, Boulware D, Kaiser HE, et al. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo. 2007;21:35-43.
33. Maia JH, Maltez A, Athayde C, et al. c-erbB2 over-expression in endometrial hyperplasia induced by estrogens. Maturitas. 2002;43:41-47.
34. Elhafey AS, Papadimitriou JC, El-Hakim MS, et al. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium. Arch Pathol Lab Med. 2001;125:872-879.
35. Ferrandina G, Ranelletti FO, Gallotta V, et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, Ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005;98:383-389.
36. Sasano H, Nagura H, Watanabe K, et al. Tenascin expression in normal and abnormal human endometrium. Mod Pathol. 1993;6:323-326.
37. Vollmer G, Siegal GP, Chiquet-Ehrismann R, et al. Tenascin expression in the human endometrium and in endometrial adenocarcinomas. Lab Invest. 1990;62:725-730.
38. Sedele M, Karaveli S, Peştereli HE, et al. Tenascin expression in normal, hyperplastic, and neoplastic endometrium. Int J Gynecol Pathol. 2002;21:161-166.
39. Harrell F. Regression Modeling Strategies. New York, NY: Springer; 2001.
40. Hosmer D, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons, Inc; 2000.
41. Steyenberg E. Clinical Prediction Models. New York, NY: Springer; 2009.
42. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
43. Morise AP, Diamond GA, Detrano R, et al. The effect of disease-prevalence adjustments on the accuracy of a logistic prediction model. Med Decis Making. 1996;16:133-142.
44. Athannasiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53 and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer. 2007;17:697-704.
45. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924-930.
46. Suthipintawong C, Wejaranayang C, Vipupinyo C. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. J Med Assoc Thai. 2008;91:1779-1784.
47. Semczuk A, Skomra D, Cybulski M, et al. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem J. 2001;33:193-200.
48. Pallares J, Bussaglia E, Martinez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol. 2005;18:719-727.
49. Norimatsu Y, Miyamoto M, Kobayashi TK, et al. Diagnostic utility of phosphatase and tensin homolog, beta-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations. Cancer. 2008;114:155-164.
50. Burbos N, Musonda P, Duncan TJ, et al. Estimating the risk of endometrial cancer in symptomatic postmenopausal women. Int J Gynecol Cancer. 2011;21:500-506.
51. Lambropoulou M, Stefanou D, Alexiadis G, et al. Cytoplasmic expression of c-erb-B2 in endometrial carcinomas. Onkologie. 2007;30:495-500.
52. Mariani A, Sebo TJ, Katzmann JA, et al. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. Anticancer Res. 2005;25:2921-2927.
53. Brys M, Semczuk A, Rechberger T, et al. Expression of ErbB-1 and ErbB-2 genes in normal and pathological human endometrium. Oncol Rep. 2007;18:261-265.
54. Suh-Burgmann E, Hung YY, Armstrong MA. Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage. Obstet Gynecol. 2009;114:523-529.
55. Phillips V, McCluggage WG. Results of a questionnaire regarding criteria for the adequacy of endometrial biopsies. J Clin Pathol. 2005;58:417-419.
56. Baak JP, Orbo A, van Diest PJ, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol. 2001;25:930-935.
57. Ørbo A,KainoT, Arnes M, et al. Prognosticmarkers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction. Acta Obstet Gynecol Scand. 2009;88:1234-1242.